American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
Upgrade
American Flag

Novavax Inc

NVAX Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Forecast
Insiders
Institutions
Compensation
Government
Ownership
News

Chart provided by TradingView

NVAX historical prices
Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of NVAX by members of U.S. Congress

Politician Type Traded
Pat Roberts Senate / R Sale (Full) $1,001 - $15,000 Oct 13, 2020
Pat Roberts Senate / R Purchase $1,001 - $15,000 Aug 17, 2020
NVAX Stock Insider Trading Activity Follow @QuiverQuant for major insider updates

---

Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
NVAX Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
NVAX Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes in NVAX holdings by institutional investors

Insider Trading

Quarterly net insider trading by NVAX's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
View Strategy Copytrade Strategy
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions

Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.

  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More about Alpha
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More about Annual Standard Deviation
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More about Annual Volatility
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More about Beta
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More about CAGR
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More about Information Ratio
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More about Max Drawdown
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More about Sharpe Ratio
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More about Treynor Ratio
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

See Pricing
schema-2
Corporate Lobbying

Government lobbying spending instances

  • $130,000 Jul 17, 2026 Issue: Health Issues
  • $140,000 Apr 20, 2026 Issue: Health Issues
  • $110,000 Jan 20, 2026 Issue: Health Issues
  • $230,000 Oct 20, 2025 Issue: Health Issues
  • $190,000 Jul 21, 2025 Issue: Health Issues
  • $170,000 Apr 28, 2025 Issue: Health Issues
  • $100,000 Jan 20, 2025 Issue: Health Issues
  • $90,000 Oct 18, 2024 Issue: Health Issues
  • $90,000 Jul 17, 2024 Issue: Health Issues
  • $120,000 Jan 19, 2024 Issue: Health Issues
  • $120,000 Oct 20, 2023 Issue: Health Issues
  • $120,000 Jul 20, 2023 Issue: Health Issues
  • $150,000 Jan 20, 2023 Issue: Health Issues
  • $110,000 Oct 21, 2022 Issue: Health Issues
  • $110,000 Jul 20, 2022 Issue: Health Issues
  • $160,000 Apr 19, 2022 Issue: Health Issues
  • $150,000 Jan 17, 2022 Issue: HEALTH ISSUES
  • $120,000 Oct 19, 2021 Issue: HEALTH ISSUES
  • $110,000 Jul 20, 2021 Issue: HEALTH ISSUES
  • $100,000 Apr 20, 2021 Issue: HEALTH ISSUES
  • $60,000 Jan 18, 2021 Issue: HEALTH ISSUES
  • $90,000 Oct 20, 2020 Issue: None
  • $50,000 Jul 22, 2020 Issue: None
  • $10,000 May 11, 2020 Issue: TAXATION/INTERNAL REVENUE CODE
  • $10,000 Jan 03, 2020 Issue: TAXATION/INTERNAL REVENUE CODE
  • $10,000 Oct 18, 2019 Issue: Taxation/Internal Revenue Code
  • $10,000 Jul 18, 2019 Issue: Health Issues Taxation/Internal Revenue Code
  • $10,000 Apr 17, 2019 Issue: Taxation/Internal Revenue Code Budget/Appropriations
  • $10,000 Jan 18, 2019 Issue: Health Issues Taxation/Internal Revenue Code
  • $10,000 Oct 10, 2018 Issue: Budget/Appropriations Health Issues Taxation/Internal Revenue Code
  • $20,000 Jul 20, 2018 Issue: Taxation/Internal Revenue Code Health Issues Budget/Appropriations
  • $20,000 Apr 18, 2018 Issue: Taxation/Internal Revenue Code Budget/Appropriations
  • $20,000 Jan 19, 2018 Issue: Taxation/Internal Revenue Code Health Issues
  • $30,000 Oct 20, 2017 Issue: Taxation/Internal Revenue Code
  • $30,000 Jul 20, 2017 Issue: Taxation/Internal Revenue Code Health Issues Budget/Appropriations
  • $10,000 Apr 20, 2017 Issue: Health Issues Budget/Appropriations
  • $20,000 Jan 20, 2017 Issue: Medicare/Medicaid Health Issues Budget/Appropriations
  • $50,000 Oct 18, 2016 Issue: Medicare/Medicaid Health Issues Budget/Appropriations
  • $10,000 Jul 25, 2016 Issue: Health Issues
  • $10,000 Jul 20, 2016 Issue: Health Issues
  • $30,000 Apr 20, 2016 Issue: Health Issues
  • $10,000 Jan 20, 2016 Issue: Health Issues
  • $10,000 Oct 20, 2015 Issue: Health Issues
  • $10,000 Jul 20, 2015 Issue: Health Issues
  • $10,000 Apr 20, 2015 Issue: Health Issues
  • $10,000 Jan 14, 2015 Issue: Health Issues
  • $15,000 Oct 17, 2014 Issue: Health Issues
  • $10,000 Sep 04, 2014 Issue: Health Issues
  • $20,000 Apr 18, 2014 Issue: Health Issues
  • $15,000 Jan 15, 2014 Issue: Health Issues
  • $10,000 Oct 14, 2013 Issue: Health Issues
  • $7,000 Jul 16, 2013 Issue: Health Issues
  • $30,000 Jul 19, 2011 Issue: Health Issues
  • $30,000 Apr 18, 2011 Issue: Health Issues
  • $30,000 Jan 19, 2011 Issue: Health Issues
  • $30,000 Oct 19, 2010 Issue: Health Issues
  • $30,000 Jul 17, 2010 Issue: Health Issues
  • $30,000 Apr 18, 2010 Issue: Health Issues
  • $30,000 Jan 20, 2010 Issue: Health Issues
  • $30,000 Oct 20, 2009 Issue: Health Issues
  • $30,000 Jul 20, 2009 Issue: Health Issues
  • $20,000 Apr 20, 2009 Issue: Financial Institutions/Investments/Securities
  • $20,000 Aug 09, 2006 Issue: Budget/Appropriations
  • $20,000 Feb 13, 2006 Issue: Budget/Appropriations
  • $20,000 Mar 26, 2002 Issue: Defense Budget/Appropriations Medical/Disease Research/Clinical Labs
Revolving Door

Former government officials who have lobbied for NVAX

38 former government officials from 23 congressional offices at 10 lobbying firms have lobbied for NVAX, most recently Jul 16, 2026.

  • Jeff Miller Congress Former Member US Congress Formerly Former Member US Congress · BALLARD PARTNERS · Jul 16, 2026
  • Mike Kelly
    John Ray House Legislative Assistant, Rep. Mike Kelly Formerly with Mike Kelly · JEFFREY J. KIMBELL & ASSOCIATES, INC. · Dec 05, 2025
  • Lamar Alexander
    John Herzog Senate Health Aide, Sen. Lamar Alexander; Special Assistant to the Assistant to the President for Legislative Affairs, Executive Office of the President Formerly with Lamar Alexander · JEFFREY J. KIMBELL & ASSOCIATES, INC. · Dec 05, 2025
  • John Cornyn
    Laura Kemper Senate Counsel, Sen. John Cornyn; Deputy Assistant Secretary for Legislation, U.S. Department of Health and Human Services; Counselor to the Secretary, U.S. Department of Health and Human Services Formerly with John Cornyn · JEFFREY J. KIMBELL & ASSOCIATES, INC. · Dec 05, 2025
  • Marsha Blackburn
    Keith Studdard House Legislative Director, Rep. Marsha Blackburn Formerly with Marsha Blackburn · JEFFREY J. KIMBELL & ASSOCIATES, INC. · Dec 05, 2025
  • Lamar Alexander
    Brett Meeks Senate Deputy Health Policy Director, Senate Committee on Health, Education, Labor and Pensions; Deputy Press Secretary, Office of Senator Lamar Alexander Formerly with Lamar Alexander · JEFFREY J. KIMBELL & ASSOCIATES, INC. · Dec 05, 2025
  • Frank Pallone, Jr.
    Stephen Holland House New Senior Health Counsel, Health Counsel - House Energy and Commerce Committee (Rep. Frank Pallone); Counsel, Legislative Assistant - Rep. Kurt Schrader Formerly with Frank Pallone, Jr. · BROWNSTEIN HYATT FARBER SCHRECK, LLP · Sep 15, 2025
  • Charles E. Schumer
    James Flood Senate New Counsel - Senate Judiciary Committee (Sen. Schumer) Formerly with Charles E. Schumer · BROWNSTEIN HYATT FARBER SCHRECK, LLP · Sep 15, 2025
See all 38 on the Revolving Door dashboard
Corporate Lobbying

NVAX Estimated quarterly lobbying spending

Revenue Breakdown

NVAX Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
NVAX Income Statement
NVAX Balance Sheet
NVAX Cash Flow
U.S. Patents

New NVAX patent grants

  • Patent Title: Methods and compositions for inducing immune responses against Mar. 26, 2024
  • Patent Title: Corona virus vaccine formulations Feb. 13, 2024
  • Patent Title: Multivalent influenza nanoparticle vaccines Feb. 13, 2024
  • Patent Title: Coronavirus vaccine formulations Jan. 03, 2023
  • Patent Title: Modified rsv f proteins and methods of their use Sep. 20, 2022
  • Patent Title: Vaccine compositions having improved stability and immunogenicity Jun. 21, 2022
  • Patent Title: Multivalent influenza nanoparticle vaccines Mar. 22, 2022
  • Patent Title: Coronavirus vaccine formulations Feb. 22, 2022
  • Patent Title: Vaccine compositions having improved stability and immunogenicity Feb. 22, 2022
  • Patent Title: Methods and compositions for inducing immune responses against clostridium difficile Sep. 21, 2021
  • Patent Title: Modified rsv f proteins and methods of their use Jul. 06, 2021
  • Patent Title: Coronavirus vaccine formulations Mar. 23, 2021
  • Patent Title: Composition comprising iscom particles and live micro-organisms Oct. 27, 2020
  • Patent Title: Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods Aug. 25, 2020
  • Patent Title: Influenza vaccine Aug. 11, 2020
  • Patent Title: Iscom preparation and use thereof Aug. 04, 2020
  • Patent Title: Functional influenza virus like particles (vlps) Aug. 04, 2020
  • Patent Title: Functional influenza virus-like particles (vlps) Feb. 04, 2020
  • Patent Title: Highly efficient influenza matrix (m1) proteins Jan. 28, 2020
  • Patent Title: Influenza vaccine Nov. 26, 2019
  • Patent Title: Vaccine compositions having improved stability and immunogenicity Oct. 01, 2019
  • Patent Title: Functional influenza virus like particles (vlps) Jan. 29, 2019
  • Patent Title: Rabies glycoprotein virus-like particles (vlps) Oct. 02, 2018
  • Patent Title: Functional influenza virus-like particles (vlps) May. 01, 2018
  • Patent Title: Highly efficient influenza matrix (m1) proteins Apr. 24, 2018
  • Patent Title: Functional influenza virus-like particles (vlps) Apr. 10, 2018
  • Patent Title: Compositions comprising iscom particles and live micro-organisms Feb. 27, 2018
  • Patent Title: Modified rsv f proteins and methods of their use Aug. 15, 2017
  • Patent Title: Rabies glycoprotein virus-like particles (vlps) Aug. 08, 2017
  • Patent Title: Modified rsv f proteins and methods of their use Aug. 01, 2017
  • Patent Title: Functional influenza virus like particles (vlps) Jul. 04, 2017
  • Patent Title: Modified rsv f proteins and methods of their use Jun. 13, 2017
  • Patent Title: Functional influenza virus-like particles (vlps) Apr. 18, 2017
  • Patent Title: Functional influenza virus-like particles (vlps) Oct. 25, 2016
  • Patent Title: Highly efficient influenza matrix (m1) proteins Oct. 11, 2016
  • Patent Title: Vlps derived from cells that do not express a viral matrix or core protein Jul. 05, 2016
  • Patent Title: Composition comprising iscom particles and live micro-organisms Dec. 08, 2015
  • Patent Title: Functional influenza virus-like particles (vlps) Nov. 10, 2015
  • Patent Title: Functional influenza virus-like particles (vlps) Sep. 29, 2015
  • Patent Title: Functional influenza virus like particles (vlps) Jun. 09, 2015
  • Patent Title: Highly efficient influenza matrix (m1) proteins Mar. 31, 2015
  • Patent Title: Functional influenza virus-like particles (vlps) Feb. 10, 2015
  • Patent Title: Quil a fraction with low toxicity and use thereof Sep. 02, 2014
  • Patent Title: Modified rsv f proteins and methods of their use May. 06, 2014
  • Patent Title: Vlps derived from cells that do not express a viral matrix or core protein Apr. 15, 2014
  • Patent Title: Functional influenza virus-like particles (vlps) Nov. 26, 2013
  • Patent Title: Avian influenza chimeric vlps Oct. 08, 2013
  • Patent Title: Functional influenza virus like particles (vlps) Aug. 13, 2013
  • Patent Title: Functional influenza virus like particles (vlps) Dec. 20, 2011
  • Patent Title: Functional influenza virus-like particles (vlps) Jul. 27, 2010
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded to NVAX from public contracts

NVAX News

Recent insights relating to NVAX

CNBC Recommendations

Recent picks made for NVAX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in NVAX

NVAX Analyst Ratings

NVAX Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
NVAX Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $NVAX stock a Buy, Sell, or Hold?

  • What is the price target for $NVAX stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

NVAX Top Shareholders
Shareholder
Shares Held
NVAX Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $NVAX stock?

  • Who owns the most shares of $NVAX stock?

  • What funds own $NVAX stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

NVAX Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view NVAX Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About NVAX

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

  • Address Gaithersburg, MD
  • Market Cap 1.7 billion
  • Employees 749
  • Industrial Classification Biological Products, (No Diagnostic Substances)

Novavax Inc (NVAX) Historical Stock Prices

Novavax Inc (NVAX) closed at $10.55 on September 23, 2026. Over the past year its adjusted close ranged from $6.22 to $11.19. Daily prices go back to January 2, 2014, 3,199 trading days in all.

  • 1 month+19.07%
  • 3 months+18.54%
  • Year to date+56.99%
  • 1 year+21.68%
  • 3 years+47.97%
  • 5 years-95.75%
  • Max-89.88%
See every congressional and insider trade on the NVAX price chart

Quiver Premium charts NVAX's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.

Upgrade to Premium

Last 12 months, newest first

Access Raw Data Daily prices since 2014 for every ticker, through the Quiver API
DateOpenHighLowCloseAdj. CloseVolume
Sep 23, 2026 10.79 10.95 10.46 10.55 10.55 5,773,245
Sep 22, 2026 10.39 11.09 10.15 10.83 10.83 7,580,684
Sep 21, 2026 10.38 10.70 10.21 10.41 10.41 6,135,452
Sep 18, 2026 9.89 10.14 9.76 10.11 10.11 11,145,562
Sep 17, 2026 9.62 10.38 9.61 10.00 10.00 8,876,144
Sep 16, 2026 9.35 9.41 9.15 9.35 9.35 2,849,467
Sep 15, 2026 9.50 9.56 9.16 9.23 9.23 3,331,569
Sep 14, 2026 9.38 9.60 9.13 9.59 9.59 3,366,869
Sep 11, 2026 9.29 9.87 9.23 9.42 9.42 6,121,466
Sep 10, 2026 9.64 9.68 9.11 9.30 9.30 5,893,316
Sep 9, 2026 10.02 10.24 9.73 9.85 9.85 4,443,785
Sep 8, 2026 10.10 10.36 9.75 10.19 10.19 4,230,871
Sep 4, 2026 10.50 10.75 10.04 10.22 10.22 5,125,027
Sep 3, 2026 10.41 10.48 9.90 10.34 10.34 6,226,630
Sep 2, 2026 10.28 10.73 9.96 10.32 10.32 5,635,817
Sep 1, 2026 9.20 10.26 9.19 10.12 10.12 10,040,575
Aug 31, 2026 9.10 9.98 9.09 9.37 9.37 7,271,750
Aug 28, 2026 9.18 9.34 8.89 9.26 9.26 4,211,771
Aug 27, 2026 9.12 9.18 8.91 9.05 9.05 3,426,679
Aug 26, 2026 9.33 9.44 9.13 9.21 9.21 3,514,522
Aug 25, 2026 9.07 9.58 8.93 9.44 9.44 7,107,633
Aug 24, 2026 8.87 8.98 8.26 8.86 8.86 5,579,176
Aug 21, 2026 8.44 9.20 8.44 8.94 8.94 10,448,189
Aug 20, 2026 8.50 8.66 8.02 8.42 8.42 5,976,486
Aug 19, 2026 8.43 8.83 8.19 8.79 8.79 11,451,112
Aug 18, 2026 7.97 8.08 7.83 7.93 7.93 2,015,486
Aug 17, 2026 8.05 8.17 7.95 8.07 8.07 1,928,257
Aug 14, 2026 8.13 8.13 7.92 8.05 8.05 2,279,571
Aug 13, 2026 8.01 8.23 7.92 8.14 8.14 3,506,533
Aug 12, 2026 7.91 7.99 7.83 7.96 7.96 2,541,803
Aug 11, 2026 7.92 8.03 7.78 7.95 7.95 2,607,366
Aug 10, 2026 7.89 7.96 7.70 7.89 7.89 3,225,294
Aug 7, 2026 7.75 8.09 7.59 7.95 7.95 5,704,173
Aug 6, 2026 7.83 7.91 7.53 7.74 7.74 4,902,632
Aug 5, 2026 7.71 7.75 7.54 7.70 7.70 3,632,834
Aug 4, 2026 7.49 7.70 7.46 7.66 7.66 3,249,410
Aug 3, 2026 7.37 7.61 7.26 7.41 7.41 2,580,451
Jul 31, 2026 7.44 7.49 7.21 7.32 7.32 3,405,996
Jul 30, 2026 7.43 7.50 7.25 7.44 7.44 2,926,392
Jul 29, 2026 7.29 7.46 7.24 7.34 7.34 2,326,892
Jul 28, 2026 7.49 7.54 7.15 7.37 7.37 2,869,430
Jul 27, 2026 7.76 7.82 7.49 7.49 7.49 3,318,592
Jul 24, 2026 7.90 7.93 7.45 7.46 7.46 3,178,300
Jul 23, 2026 7.83 7.91 7.72 7.83 7.83 2,389,394
Jul 22, 2026 8.14 8.18 7.87 7.91 7.91 2,637,232
Jul 21, 2026 7.91 8.13 7.87 8.07 8.07 2,530,269
Jul 20, 2026 8.25 8.30 7.84 7.88 7.88 3,029,402
Jul 17, 2026 8.13 8.29 8.05 8.21 8.21 2,265,585
Jul 16, 2026 8.28 8.37 8.15 8.24 8.24 2,403,348
Jul 15, 2026 8.40 8.50 8.26 8.43 8.43 2,537,759
Jul 14, 2026 8.88 8.91 8.42 8.42 8.42 3,798,121
Jul 13, 2026 9.13 9.27 8.80 8.91 8.91 3,855,264
Jul 10, 2026 9.38 9.39 8.94 9.33 9.33 5,096,243
Jul 9, 2026 9.45 9.69 9.34 9.40 9.40 2,718,592
Jul 8, 2026 9.28 9.54 9.15 9.35 9.35 3,793,610
Jul 7, 2026 9.34 9.48 8.88 9.46 9.46 4,517,345
Jul 6, 2026 9.50 9.65 9.13 9.35 9.35 2,958,090
Jul 2, 2026 9.56 10.12 9.45 9.74 9.74 4,850,708
Jul 1, 2026 9.37 9.64 9.29 9.46 9.46 4,568,968
Jun 30, 2026 9.33 9.77 9.28 9.42 9.42 3,984,674
Jun 29, 2026 8.92 9.38 8.88 9.36 9.36 4,039,729
Jun 26, 2026 8.53 8.94 8.53 8.88 8.88 8,409,598
Jun 25, 2026 8.90 8.98 8.27 8.56 8.56 4,370,755
Jun 24, 2026 9.15 9.36 8.86 8.90 8.90 3,507,759
Jun 23, 2026 8.81 9.59 8.81 9.00 9.00 4,235,736
Jun 22, 2026 9.16 9.37 8.96 9.00 9.00 3,706,432
Jun 18, 2026 9.68 9.99 9.08 9.13 9.13 9,458,291
Jun 17, 2026 9.19 9.72 9.12 9.50 9.50 3,901,671
Jun 16, 2026 9.22 9.60 8.95 9.20 9.20 4,168,434
Jun 15, 2026 9.17 9.38 9.06 9.21 9.21 3,573,034
Jun 12, 2026 9.07 9.30 8.79 8.88 8.88 2,592,147
Jun 11, 2026 8.54 9.09 8.45 9.03 9.03 3,573,358
Jun 10, 2026 8.63 8.84 8.47 8.56 8.56 3,098,776
Jun 9, 2026 8.75 8.86 8.35 8.67 8.67 4,589,829
Jun 8, 2026 9.56 9.69 8.60 8.62 8.62 6,864,236
Jun 5, 2026 9.97 10.13 9.26 9.49 9.49 4,583,764
Jun 4, 2026 10.17 10.59 10.10 10.19 10.19 5,248,628
Jun 3, 2026 10.14 10.31 9.94 10.20 10.20 3,090,597
Jun 2, 2026 10.40 10.40 9.81 10.21 10.21 4,652,959
Jun 1, 2026 10.82 10.88 10.50 10.51 10.51 4,682,722
May 29, 2026 10.26 11.19 10.21 10.97 10.97 7,161,696
May 28, 2026 10.91 10.93 10.12 10.32 10.32 7,442,208
May 27, 2026 10.48 11.61 10.48 11.09 11.09 9,799,912
May 26, 2026 9.38 10.52 9.38 10.46 10.46 8,324,001
May 22, 2026 8.94 9.23 8.92 9.21 9.21 4,434,612
May 21, 2026 9.15 9.23 8.94 8.98 8.98 3,592,896
May 20, 2026 8.97 9.46 8.93 9.27 9.27 4,949,589
May 19, 2026 8.76 8.96 8.64 8.90 8.90 2,988,794
May 18, 2026 9.22 9.33 8.71 8.93 8.93 4,837,341
May 15, 2026 9.13 9.32 8.93 9.06 9.06 4,070,807
May 14, 2026 9.15 9.37 8.86 9.35 9.35 4,610,175
May 13, 2026 9.43 9.51 9.16 9.23 9.23 5,174,304
May 12, 2026 9.23 9.93 9.20 9.62 9.62 6,135,996
May 11, 2026 10.55 10.74 9.30 9.50 9.50 10,343,093
May 8, 2026 9.36 10.75 9.32 10.11 10.11 13,354,044
May 7, 2026 9.67 10.20 9.16 9.23 9.23 9,197,512
May 6, 2026 8.56 9.56 8.35 9.36 9.36 16,482,982
May 5, 2026 8.10 8.16 7.81 8.10 8.10 3,629,481
May 4, 2026 8.03 8.36 7.96 8.03 8.03 3,502,922
May 1, 2026 7.90 8.08 7.86 8.04 8.04 3,114,226
Apr 30, 2026 8.01 8.27 7.92 7.92 7.92 2,817,353
Apr 29, 2026 7.83 7.99 7.71 7.97 7.97 2,865,473
Apr 28, 2026 8.08 8.10 7.87 7.92 7.92 3,290,006
Apr 27, 2026 8.17 8.33 7.97 8.07 8.07 2,656,599
Apr 24, 2026 8.21 8.29 8.07 8.22 8.22 1,788,656
Apr 23, 2026 8.43 8.50 7.97 8.15 8.15 3,580,280
Apr 22, 2026 8.54 8.65 8.40 8.45 8.45 3,523,197
Apr 21, 2026 8.67 8.74 8.41 8.49 8.49 3,960,452
Apr 20, 2026 8.73 8.85 8.60 8.67 8.67 2,842,678
Apr 17, 2026 8.96 8.99 8.75 8.84 8.84 2,465,392
Apr 16, 2026 8.78 8.80 8.46 8.64 8.64 2,005,999
Apr 15, 2026 8.38 8.79 8.38 8.69 8.69 2,962,274
Apr 14, 2026 8.17 8.40 8.13 8.39 8.39 3,304,062
Apr 13, 2026 8.08 8.31 7.99 8.11 8.11 2,774,062
Apr 10, 2026 8.52 8.55 8.02 8.12 8.12 3,450,273
Apr 9, 2026 8.41 8.60 8.32 8.54 8.54 2,307,763
Apr 8, 2026 8.57 8.60 8.18 8.42 8.42 3,730,130
Apr 7, 2026 7.80 8.04 7.71 7.98 7.98 2,373,376
Apr 6, 2026 7.78 8.13 7.77 7.97 7.97 2,798,632
Apr 2, 2026 7.70 7.91 7.57 7.70 7.70 4,662,730
Apr 1, 2026 8.19 8.32 8.00 8.02 8.02 2,793,623
Mar 31, 2026 8.27 8.39 7.71 8.14 8.14 5,998,569
Mar 30, 2026 8.41 8.42 7.94 8.09 8.09 4,152,588
Mar 27, 2026 8.84 8.96 8.44 8.45 8.45 3,942,822
Mar 26, 2026 9.01 9.29 8.75 8.95 8.95 3,071,393
Mar 25, 2026 9.39 9.60 9.22 9.34 9.34 2,708,871
Mar 24, 2026 9.52 9.72 9.25 9.26 9.26 3,175,302
Mar 23, 2026 9.64 10.00 9.44 9.72 9.72 5,300,961
Mar 20, 2026 9.84 10.00 9.42 9.62 9.62 5,683,771
Mar 19, 2026 9.71 9.82 9.38 9.74 9.74 3,876,731
Mar 18, 2026 10.63 10.80 10.00 10.01 10.01 3,908,770
Mar 17, 2026 10.05 10.94 10.03 10.64 10.64 6,109,347
Mar 16, 2026 10.42 10.47 9.95 10.08 10.08 3,346,060
Mar 13, 2026 10.42 10.61 10.12 10.23 10.23 2,859,278
Mar 12, 2026 10.78 10.81 10.27 10.30 10.30 3,609,707
Mar 11, 2026 10.70 11.05 10.45 10.80 10.80 5,184,858
Mar 10, 2026 10.57 10.82 10.44 10.69 10.69 3,609,630
Mar 9, 2026 9.79 10.72 9.79 10.55 10.55 5,568,027
Mar 6, 2026 9.75 10.05 9.53 9.98 9.98 3,884,727
Mar 5, 2026 9.56 10.03 9.52 9.99 9.99 4,560,708
Mar 4, 2026 9.68 10.11 9.14 9.89 9.89 5,075,558
Mar 3, 2026 9.75 10.06 9.40 9.49 9.49 4,941,929
Mar 2, 2026 9.78 10.34 9.70 10.11 10.11 4,189,617
Feb 27, 2026 11.15 11.15 9.81 10.14 10.14 10,243,355
Feb 26, 2026 9.82 11.97 9.70 11.19 11.19 23,919,407
Feb 25, 2026 9.52 9.74 9.29 9.53 9.53 4,201,607
Feb 24, 2026 9.35 9.77 9.31 9.46 9.46 2,919,379
Feb 23, 2026 9.14 9.60 9.10 9.36 9.36 2,961,446
Feb 20, 2026 9.06 9.53 9.04 9.20 9.20 3,416,865
Feb 19, 2026 8.70 9.30 8.53 9.22 9.22 3,957,205
Feb 18, 2026 8.65 8.85 8.56 8.69 8.69 1,768,700
Feb 17, 2026 8.51 8.85 8.49 8.65 8.65 2,289,062
Feb 13, 2026 8.55 8.91 8.48 8.70 8.70 3,218,881
Feb 12, 2026 8.97 9.19 8.25 8.42 8.42 4,112,369
Feb 11, 2026 8.91 9.28 8.54 8.97 8.97 5,041,522
Feb 10, 2026 8.69 9.02 8.60 8.75 8.75 3,718,352
Feb 9, 2026 8.19 8.73 8.02 8.70 8.70 4,000,524
Feb 6, 2026 8.01 8.31 7.84 8.25 8.25 3,250,544
Feb 5, 2026 8.17 8.32 7.83 7.87 7.87 4,159,441
Feb 4, 2026 8.42 8.62 8.16 8.27 8.27 3,499,392
Feb 3, 2026 8.64 8.85 8.09 8.37 8.37 3,775,317
Feb 2, 2026 8.67 8.87 8.44 8.69 8.69 3,331,897
Jan 30, 2026 9.22 9.29 8.65 8.85 8.85 5,015,977
Jan 29, 2026 9.25 9.60 9.23 9.44 9.44 4,492,924
Jan 28, 2026 9.74 9.94 9.16 9.23 9.23 5,322,463
Jan 27, 2026 9.75 10.20 9.62 9.82 9.82 6,801,047
Jan 26, 2026 9.32 10.02 9.25 9.63 9.63 6,846,553
Jan 23, 2026 9.70 9.70 9.15 9.17 9.17 7,589,644
Jan 22, 2026 9.86 10.13 9.49 9.75 9.75 9,392,765
Jan 21, 2026 8.28 9.98 8.20 9.90 9.90 16,572,711
Jan 20, 2026 8.22 8.75 7.98 8.20 8.20 11,870,548
Jan 16, 2026 7.77 8.33 7.73 8.01 8.01 5,448,521
Jan 15, 2026 8.04 8.15 7.75 7.78 7.78 5,886,285
Jan 14, 2026 8.47 8.53 7.89 8.19 8.19 7,551,554
Jan 13, 2026 7.85 8.81 7.84 8.67 8.67 11,161,772
Jan 12, 2026 7.30 7.79 7.15 7.75 7.75 3,817,551
Jan 9, 2026 7.38 7.55 7.25 7.27 7.27 2,787,703
Jan 8, 2026 7.49 7.55 7.31 7.34 7.34 2,803,870
Jan 7, 2026 7.51 7.75 7.45 7.62 7.62 4,270,617
Jan 6, 2026 7.22 7.67 7.22 7.44 7.44 4,275,195
Jan 5, 2026 7.10 7.36 7.09 7.25 7.25 3,204,609
Jan 2, 2026 6.76 7.20 6.76 7.13 7.13 3,896,482
Dec 31, 2025 6.70 6.74 6.59 6.72 6.72 2,759,722
Dec 30, 2025 6.81 6.83 6.68 6.72 6.72 2,765,172
Dec 29, 2025 6.75 6.87 6.71 6.82 6.82 2,920,194
Dec 26, 2025 6.87 6.90 6.77 6.83 6.83 1,994,697
Dec 24, 2025 6.78 7.00 6.78 6.94 6.94 1,782,067
Dec 23, 2025 6.85 6.89 6.74 6.80 6.80 2,685,748
Dec 22, 2025 6.71 6.98 6.68 6.89 6.89 3,019,468
Dec 19, 2025 6.68 6.87 6.65 6.66 6.66 6,920,371
Dec 18, 2025 6.60 6.72 6.55 6.68 6.68 3,934,698
Dec 17, 2025 6.53 6.76 6.50 6.53 6.53 3,578,641
Dec 16, 2025 6.51 6.60 6.36 6.54 6.54 3,289,883
Dec 15, 2025 6.57 6.61 6.49 6.58 6.58 3,157,787
Dec 12, 2025 6.70 6.71 6.43 6.57 6.57 2,927,294
Dec 11, 2025 6.68 6.84 6.64 6.69 6.69 2,648,382
Dec 10, 2025 6.64 6.79 6.57 6.74 6.74 3,164,153
Dec 9, 2025 6.71 6.86 6.60 6.66 6.66 4,549,868
Dec 8, 2025 6.99 7.04 6.66 6.78 6.78 3,190,479
Dec 5, 2025 6.85 6.91 6.77 6.91 6.91 3,721,839
Dec 4, 2025 6.78 6.87 6.73 6.86 6.86 2,086,600
Dec 3, 2025 6.60 6.85 6.59 6.84 6.84 3,395,421
Dec 2, 2025 6.71 6.73 6.56 6.60 6.60 2,542,943
Dec 1, 2025 6.87 6.92 6.68 6.69 6.69 2,692,723
Nov 28, 2025 6.97 7.06 6.90 7.05 7.05 1,523,797
Nov 26, 2025 6.77 6.98 6.72 6.95 6.95 2,720,105
Nov 25, 2025 6.63 6.76 6.61 6.69 6.69 2,558,149
Nov 24, 2025 6.46 6.65 6.41 6.63 6.63 4,087,515
Nov 21, 2025 6.25 6.54 6.25 6.47 6.47 4,049,485
Nov 20, 2025 6.41 6.60 6.20 6.22 6.22 3,939,993
Nov 19, 2025 6.61 6.80 6.27 6.34 6.34 6,697,890
Nov 18, 2025 6.61 6.71 6.51 6.57 6.57 4,122,206
Nov 17, 2025 6.91 6.98 6.70 6.80 6.80 5,576,253
Nov 14, 2025 6.92 7.15 6.90 6.97 6.97 3,489,398
Nov 13, 2025 7.13 7.34 7.02 7.06 7.06 5,683,908
Nov 12, 2025 7.39 7.46 7.13 7.20 7.20 4,959,899
Nov 11, 2025 7.17 7.53 7.09 7.44 7.44 3,690,094
Nov 10, 2025 7.56 7.60 7.08 7.11 7.11 6,454,832
Nov 7, 2025 7.46 7.64 7.28 7.44 7.44 5,056,721
Nov 6, 2025 7.53 7.92 7.40 7.59 7.59 5,505,998
Nov 5, 2025 7.54 7.87 7.51 7.69 7.69 5,038,632
Nov 4, 2025 7.68 7.86 7.50 7.51 7.51 4,779,547
Nov 3, 2025 8.38 8.40 7.88 7.91 7.91 4,337,979
Oct 31, 2025 8.33 8.54 8.27 8.40 8.40 3,503,882
Oct 30, 2025 8.30 8.66 8.25 8.43 8.43 3,039,600
Oct 29, 2025 8.50 8.58 8.28 8.38 8.38 2,660,566
Oct 28, 2025 8.75 8.75 8.40 8.52 8.52 2,106,786
Oct 27, 2025 8.60 8.75 8.52 8.70 8.70 2,696,147
Oct 24, 2025 8.59 8.65 8.43 8.52 8.52 2,759,559
Oct 23, 2025 8.47 8.52 8.24 8.36 8.36 3,062,430
Oct 22, 2025 8.41 8.55 8.19 8.46 8.46 3,949,788
Oct 21, 2025 8.71 8.78 8.56 8.59 8.59 4,210,567
Oct 20, 2025 8.20 8.82 8.19 8.79 8.79 5,920,764
Oct 17, 2025 8.27 8.36 8.02 8.10 8.10 6,181,811
Oct 16, 2025 8.93 9.10 8.46 8.48 8.48 5,195,286
Oct 15, 2025 8.94 9.34 8.85 8.91 8.91 5,805,916
Oct 14, 2025 8.66 9.04 8.53 8.89 8.89 5,499,218
Oct 13, 2025 8.43 8.75 8.33 8.62 8.62 4,283,586
Oct 10, 2025 8.61 8.69 8.24 8.33 8.33 4,519,441
Oct 9, 2025 8.92 8.96 8.49 8.59 8.59 4,757,020
Oct 8, 2025 9.27 9.60 8.80 8.90 8.90 5,016,619
Oct 7, 2025 9.12 9.33 8.95 9.22 9.22 4,219,028
Oct 6, 2025 9.50 9.53 9.06 9.08 9.08 4,102,168
Oct 3, 2025 9.59 9.75 9.24 9.46 9.46 5,007,962
Oct 2, 2025 9.58 9.75 9.30 9.55 9.55 4,330,218
Oct 1, 2025 8.74 9.63 8.63 9.50 9.50 8,931,811
Sep 30, 2025 8.51 8.73 8.32 8.67 8.67 3,194,776
Sep 29, 2025 8.59 8.68 8.47 8.57 8.57 2,489,951
Sep 26, 2025 8.33 8.55 8.16 8.55 8.55 3,278,896
Sep 25, 2025 8.48 8.48 8.18 8.34 8.34 4,498,385
Sep 24, 2025 8.70 8.95 8.63 8.64 8.64 2,711,380
Sep 23, 2025 8.90 9.04 8.65 8.67 8.67 3,888,082

Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.

Need daily prices for every ticker, in code?

The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.

Explore the Quiver API
Novavax Inc Executive Compensation

We estimate that -- received a compensation of -- in --, making them the highest paid executive at NVAX, per a recent SEC DEF 14A filing. We estimate that the median employee at NOVAVAX INC is paid $161,162.



Name
Role
Salary
Bonus
Stock/Option Awards
Total Compensation